Drug intelligence / Profile preview

TJAOA101 (Tongji Hospital)

Development stage: Unknown
Lead developer: Tongji Hospital
Administration: Oral

Overview

TJAOA101 (Tongji anti-ovarian aging 101) is a traditional Chinese medicine (TCM) herbal compound formula developed by Tongji Hospital of Huazhong University of Science and Technology. It is specifically formulated for the treatment of premature ovarian insufficiency (POI) and diminished ovarian reserve (DOR). The compound is administered orally and is intended to restore ovarian function, as measured by improvements in anti-Müllerian hormone (AMH) levels, follicle-stimulating hormone (FSH) levels, and antral follicle count (AFC). It is currently undergoing evaluation in multicenter, prospective clinical trials to validate its safety and therapeutic efficacy in women of reproductive age (18-40 years).

Other names: Chinese herbal compound TJAOA101

Beyond the preview

Go deeper on TJAOA101 (Tongji Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJAOA101 (Tongji Hospital).

Explore the full profile